Maarten van der Doelen

Chapter 6

Platelet count (x 10 9 /L) 180 244 [206-289] 139 249 [208-289] 33 241 [198-295] 0.616 PSA level (µg/L) 179 166 [59-417] 139 130 [54-400] 32 249 [82-499] 0.125

0.859 Denosumab 177 48 (27.1) 136 39 (28.7) 33 8 (24.2)

ECOG performance status ECOG 0 172 91 (52.9) 134 74 (55.2) 31 15 (48.4) 0.784 ECOG 1 172 64 (37.2) 134 48 (35.8) 31 13 (41.9) ECOG 2-3 172 17 (9.9) 134 12 (9.0) 31 3 (9.7)

LD level (U/L) 166 233 [198-302] 129 219 [198-282] 29 274 [210-392] 0.013 LD < 250 166 96 (57.8) 129 82 (63.6) 29 12 (41.1) 0.028

Hemoglobin (g/dL) 180 12.3 [11.4-13.2] 139 12.6 [11.6-13.4] 33 11.8 [10.5-12.6] 0.001 Hb ≥ 10 180 168 (93.3) 139 133 (95.7) 33 28 (84.8) 0.022 Hb < 10 180 12 (6.7) 139 6 (4.3) 33 5 (15.2)

ALP level (U/L) 180 156 [95-264] 139 125 [85-228] 33 216 [145-348] <0.001 ALP < 115 180 67 (37.2) 139 66 (47.5) 33 0 (0.0) <0.001

P value n median [IQR] or n (%) n median [IQR] or n (%) n median [IQR] or n (%) None 177 89 (50.3) 136 68 (50.0) 33 17 (51.5)

Bisphosphonates 177 40 (22.6) 136 29 (21.3) 33 8 (24.2)

LD ≥ 250 166 70 (42.2) 129 47 (36.4) 29 17 (58.6) 1 Docetaxel was administered as upfront chemotherapy in hormone sensitive prostate cancer in four patients (2.2%). 2 Four patients (2.2%) received cabazitaxel chemotherapy without prior docetaxel chemotherapy. ALP, alkaline phosphatase; CRPC, castration-resistant prostate cancer; ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range; ISUP, International Society of Urological Pathology; LD, lactate dehydrogenase; mo, months; PSA, Prostate-specific antigen; SRE, skeletal related event; Y, years.

ALP ≥ 115 180 113 (62.8) 139 73 (52.5) 33 33 (100.0)

Subgroup 4 (N=33)

Subgroups 1-3 (N=139)

Complete cohort (N=180)

Table 1. Continued.

162